DD
Therapeutic Areas
Helocyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Triplex (V160) | Prevention of CMV reactivation in CMV-seropositive hematopoietic stem cell transplant recipients | Phase 2 |
| PEP-CMV | Cytomegalovirus (CMV) infection | Pre-clinical |
| Drug | Indication | Phase |
|---|---|---|
| Triplex (V160) | Prevention of CMV reactivation in CMV-seropositive hematopoietic stem cell transplant recipients | Phase 2 |
| PEP-CMV | Cytomegalovirus (CMV) infection | Pre-clinical |